Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Popp, Felix C ^a   Fillenberg, Barbara ^a   Eggenhofer, Elke ^a   Renner, Philipp ^a   Dillmann, Johannes ^a   Benseler, Volker ^a   Schnitzbauer, Andreas A ^a   Hutchinson, James ^a   Deans, Robert ^b   Ladenheim, Deborah ^b   Graveen, Cheryl A ^b   Zeman, Florian ^a   Koller, Michael ^a   Hoogduijn, Martin J ^c   Geissler, Edward K ^a   Schlitt, Hans J ^a   Dahlke, Marc H ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b ATHERSYS INC   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID; PREDNISOLONE; STEROID; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADHERENT CELL; ADULT; ADULT STEM CELL; ARTICLE; BILIARY TRACT INFECTION; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; FEASIBILITY STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER REGENERATION; LIVER TRANSPLANTATION; MALE; MULTIPOTENT ADULT STEM CELL; MULTIPOTENT STEM CELL; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE CARE; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; CLINICAL TRIAL; FOLLOW UP; PROFESSIONAL STANDARD; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

ADULT; ADULT STEM CELLS; CLINICAL TRIALS DATA MONITORING COMMITTEES; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MULTIPOTENT STEM CELLS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION;

EID: 79960655506     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-124     Document Type: Article

References (56)

1. Lee TH, Shah N, Pedersen RA, Kremers WK, Rosen CB, Klintmalm GB, Kim WR. Survival after liver transplantation: Is racial disparity inevitable?. Hepatology 2007, 46:1491-1497. 10.1002/hep.21830, 17929234.
2. Northup PG, Pruett TL, Stukenborg GJ, Berg CL. Survival after adult liver transplantation does not correlate with transplant center case volume in the MELD era. Am J Transplant 2006, 6:2455-2462. 10.1111/j.1600-6143.2006.01501.x, 16925567.
3. Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. TransplantProc 2004, 36:234S-239S.
4. Christians U, Kohlhaw K, Budniak J, Bleck JS, Schottmann R, Schlitt HJ, Almeida VM, Deters M, Wonigeit K, Pichlmayr R. Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicity. EurJClinPharmacol 1991, 41:285-290.
5. Mueller AR, Platz KP, Schattenfroh N, Bechstein WO, Christe W, Neuhaus P. Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients. TransplInt 1994, 7(Suppl 1):S37-S42.
6. Kalil AC, Dakroub H, Freifeld AG. Sepsis and solid organ transplantation. Curr Drug Targets 2007, 8:533-541. 10.2174/138945007780362746, 17430124.
7. Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C, Tzakis AG, Starzl TE, Ho M. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) 1988, 67:132-143.
8. Fulginiti VA, Scribner R, Groth CG, Putnam CW, Brettschneider L, Gilbert S, Porter KA, Starzl TE. Infections in recipients of liver homografts. N Engl J Med 1968, 279:619-626. 10.1056/NEJM196809192791202, 2772060, 4299208.
9. Geissler EKSH. The relation between immunosuppressive agents and malignancy. Curr Opin Organ Transplant 2004, 9:394.
10. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009, 125:1747-1754. 10.1002/ijc.24439, 19444916.
11. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009, 137:2010-2017. 10.1053/j.gastro.2009.08.070, 2789872, 19766646.
12. Eurotransplant Yearly statisitcs 2009. 2009, Eurotransplant.
13. Gastaca M. Extended criteria donors in liver transplantation: adapting donor quality and recipient. Transplant Proc 2009, 41:975-979. 10.1016/j.transproceed.2009.02.016, 19376402.
14. Lucidi V, Lemye AC, Baire L, Buggenhout A, Hoang AD, Loi P, Mboti F, Mikhailski D, Closset J, Gelin M, et al. Use of marginal donors for liver transplantation: a single-center experience within the Eurotransplant patient-driven allocation system. Transplant Proc 2007, 39:2668-2671. 10.1016/j.transproceed.2007.08.004, 17954203.
15. Mittler J, Pascher A, Neuhaus P, Pratschke J. The utility of extended criteria donor organs in severely ill liver transplant recipients. Transplantation 2008, 86:895-896. 10.1097/TP.0b013e318186ad7a, 18852650.
16. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822. 10.1182/blood-2004-04-1559, 15494428.
17. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49. 10.1038/nature00870, 12077603.
18. Reyes M, Verfaillie CM. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci 2001, 938:231-233. discussion 233-235.
19. Boozer S, Lehman N, Lakshmipathy U, Love B, Raber A, Maitra A, Deans R, Rao MS, Ting AE. Global Characterization and Genomic Stability of Human MultiStem, A Multipotent Adult Progenitor Cell. J Stem Cells 2009, 4:17-28.
20. Mays RW, van't Hof W, Ting AE, Perry R, Deans R. Development of adult pluripotent stem cell therapies for ischemic injury and disease. Expert Opin Biol Ther 2007, 7:173-184. 10.1517/14712598.7.2.173, 17250456.
21. Van Bokkelen G. Company profile: Athersys. Regen Med 2011, 6:39-43. 10.2217/rme.10.90, 21175285.
22. Highfill SL, Kelly RM, O'shaughnessy MJ, Zhou Q, Xia L, Panoskaltsis-Mortari A, Taylor PA, Tolar J, Blazar BR. Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming. Blood 2009, 114:693-701. 10.1182/blood-2009-03-213850, 2713464, 19458354.
23. Aranguren XL, Pelacho B, Penuelas I, Abizanda G, Uriz M, Ecay M, Collantes M, Arana M, Beerens M, Coppiello G, et al. MAPC transplantation confers a more durable benefit than AC133+ cell transplantation. Cell Transplant 2010,
24. Dimomeletis I, Deindl E, Zaruba M, Groebner M, Zahler S, Laslo SM, David R, Kostin S, Deutsch MA, Assmann G, et al. Assessment of human MAPCs for stem cell transplantation and cardiac regeneration after myocardial infarction in SCID mice. Exp Hematol 2010, 38:1105-1114. 10.1016/j.exphem.2010.06.013, 20621157.
25. Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, Verfaillie CM. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002, 109:1291-1302. 150983, 12021244.
26. Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, Geissler EK, Piso P, Schlitt HJ, Dahlke MH. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 2008,
27. Eggenhofer E, Steinmann JF, Renner P, Slowik P, Piso P, Geissler EK, Schlitt HJ, Dahlke MH, Popp FC. Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol 2011, 24:157-163. 10.1016/j.trim.2010.12.002, 21194567.
28. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, Bartholomew A, Garcia B, Wang H. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009, 9:1760-1772. 10.1111/j.1600-6143.2009.02721.x, 19563344.
29. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, Cavinato RA, Todeschini M, Solini S, Sonzogni A, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008, 181:3933-3946.
30. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, Dahlke MH. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006, 81:1589-1595. 10.1097/01.tp.0000209919.90630.7b, 16770249.
31. Scherer MN, Banas B, Mantouvalou K, Schnitzbauer A, Obed A, Kramer BK, Schlitt HJ. Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg 2007, 392:511-523. 10.1007/s00423-007-0188-z, 17450373.
32. Cabezuelo JB, Ramirez P, Rios A, Acosta F, Torres D, Sansano T, Pons JA, Bru M, Montoya M, Bueno FS, et al. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006, 69:1073-1080. 10.1038/sj.ki.5000216, 16528257.
33. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001, 72:1934-1939. 10.1097/00007890-200112270-00012, 11773892.
34. Lebron Gallardo M, Herrera Gutierrez ME, Seller Perez G, Curiel Balsera E, Fernandez Ortega JF, Quesada Garcia G. Risk factors for renal dysfunction in the postoperative course of liver transplant. Liver Transpl 2004, 10:1379-1385. 10.1002/lt.20215, 15497160.
35. Schrem H, Luck R, Becker T, Nashan B, Klempnauer J. Update on liver transplantation using cyclosporine. Transplant Proc 2004, 36:2525-2531. 10.1016/j.transproceed.2004.10.023, 15621081.
36. Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, Rostaing L, Rimola A, Marshall S, Mayer AD. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009, 9:327-336. 10.1111/j.1600-6143.2008.02493.x, 19120077.
37. Schnitzbauer AA, Doenecke A, Sothmann JL, Loss M, Farkas SA, Hartl J, Tsui T-Y, Baier L, Kirchner G, Obed A, et al. Improved Outcome after 'Bottom-Up' Immunosuppression in Liver Transplant Recipients with Preoperative Renal Impairment. Eur Surg Res 2010, 45:356-367. 10.1159/000321702, 21088426.
38. Schnitzbauer AA, Scherer MN, Rochon J, Sothmann J, Farkas SA, Loss M, Geissler EK, Obed A, Schlitt HJ. Study Protocol: A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients with Impaired Renal Function. PATRON-Study. 2010, 1-7.
39. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586. 10.1016/S0140-6736(08)60690-X, 18468541.
40. Demirkiran A, Hendrikx TK, Baan CC, van der Laan LJ. Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: does in vitro evidence translate to the clinical setting?. Transplantation 2008, 85:783-789. 10.1097/TP.0b013e318166910b, 18360256.
41. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004, 4:665-674. 10.1038/nri1435, 15343366.
42. Vondran FW, Timrott K, Tross J, Kollrich S, Schwarz A, Lehner F, Klempnauer J, Becker T, Schwinzer R. Impact of basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation. Transpl Int 2010, 23:514-523. 10.1111/j.1432-2277.2009.01013.x, 19951265.
43. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008, 8:2086-2096. 10.1111/j.1600-6143.2008.02377.x, 3087374, 18828769.
44. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman S, Craciun L, Sergeant R, Brouard S, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010, 120:1848-1861. 10.1172/JCI39922, 2877932, 20501943.
45. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010, 120:1836-1847. 10.1172/JCI39933, 2877933, 20501946.
46. Keeren K, Friedrich M, Gebuhr I, Philipp S, Sabat R, Sterry W, Brandt C, Meisel C, Grutz G, Volk HD, Sawitzki B. Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies. J Immunol 2009, 183:4077-4087. 10.4049/jimmunol.0804351, 19684086.
47. Martinez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, Benitez C, Pons JA, Parrilla P, Ramirez P, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008, 118:2845-2857. 2483684, 18654667.
48. Sawitzki B, Bushell A, Steger U, Jones N, Risch K, Siepert A, Lehmann M, Schmitt-Knosalla I, Vogt K, Gebuhr I, et al. Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant 2007, 7:1091-1102. 10.1111/j.1600-6143.2007.01768.x, 17456197.
49. Tolar J, O'shaughnessy MJ, Panoskaltsis-Mortari A, McElmurry RT, Bell S, Riddle M, McIvor RS, Yant SR, Kay MA, Krause D, et al. Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. Blood 2006, 107:4182-4188. 10.1182/blood-2005-08-3289, 1895284, 16410448.
50. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008, 29:2276-2315.
51. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824.
52. del Pozo JL. Update and actual trends on bacterial infections following liver transplantation. World J Gastroenterol 2008, 14:4977-4983. 10.3748/wjg.14.4977, 2742922, 18763277.
53. Kovacsovics-Bankowski M, Streeter PR, Mauch KA, Frey MR, Raber A, van't Hof W, Deans R, Maziarz RT. Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol 2009, 255:55-60. 10.1016/j.cellimm.2008.10.004, 19022422.
54. Hoogduijn MJ, Crop MJ, Korevaar SS, Peeters AM, Eijken M, Maat LP, Balk AH, Weimar W, Baan CC. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation 2008, 86:1283-1291. 10.1097/TP.0b013e31818aa536, 19005411.
55. Athersys web site. , http://www.athersys.com
56. Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R. Mesenchymal stem cells for clinical application. Vox Sang 2010, 98:93-107. 10.1111/j.1423-0410.2009.01227.x, 19663934.